HER2-Low Breast Cancer: Current Landscape and Future Prospects
Yelena Shirman,Shlomit Lubovsky,Ayelet Shai
DOI: https://doi.org/10.2147/BCTT.S366122
2023-08-15
Breast Cancer: Targets and Therapy
Abstract:Yelena Shirman, Shlomit Lubovsky, Ayelet Shai Division of Oncology, Rambam Health Care Campus, Haifa, Israel Correspondence: Ayelet Shai, Division of Oncology, Rambam Health Care Campus, HaAliya HaShniya St 8, PO Box 9602, Haifa, 3109601, Israel, Tel +972-47776400, Email More than 50% of breast cancers are currently defined as "Human epidermal growth factor receptor 2 (HER2) low breast cancer (BC)", with HER2 immunohistochemistry (IHC) scores of +1 or +2 with a negative fluorescence in situ hybridization (FISH) test. In most studies that compared the clinical and biological characteristics of HER2-low BC with HER2-negative BC, HER2-low was not associated with unique clinical and molecular characteristics, and it seems that the importance of HER2 in these tumors is being a docking site for the antibody portion of antibody drug conjugates (ADCs). Current pathological methods may underestimate the proportion of BCs that express low levels of HER2 due to analytical limitations and tumor heterogeneity. In this review we summarize and contextualize the most recent literature on HER2-low breast cancers, including clinical and translational studies We also review the challenges of assessing low HER2 expression in BC and discuss the current and future therapeutic landscape for these tumors. Keywords: HER2-low, ERBB2 low, breast cancer, HER2 targeted therapy, trastuzumab, trastuzumab-deruxtecan, T-DXd HER2 belongs to the epidermal growth factor (EGF) tyrosine kinase receptor family. HER2 is unique for both its functional characteristics as an orphan receptor that heterodimerizes with other tyrosine kinase receptors (TKIs) and its high oncogenic potential. 1 The HER2 gene is amplified in 15–20% of breast cancers, resulting in markedly increased HER2 protein content on the cell surface and enhanced signal transduction through HER2 heterodimers. 2 These tumors were associated with a higher risk of relapse and shorter survival before anti-HER2 treatments were available; 3,4 however, the development of trastuzumab, pertuzumab and other HER2 targeting agents revolutionized the treatment and improved the prognosis of patients with advanced 5,6 and early 7–9 HER2-positive breast cancer. HER2 positivity is defined by a circumferential, complete, and intense membrane immunohistochemistry (IHC) staining in >10% of the tumor, defined as IHC +3, or a weak to moderate complete membrane staining in >10% of tumor cells (IHC +2) with a positive ISH test. 10 Trials designed to test the benefit of trastuzumab and of trastuzumab-emtansine in breast cancers with lower HER2 expression failed to show the benefit of these HER2 targeting agents, 11,12 and these tumors were defined as "HER2-negative". However, post-hoc analyses of the seminal adjuvant trastuzumab trials did not find an association between the degree of HER2 amplification or chromosome 17 polysomy and benefit from trastuzumab. 13,14 In addition, analyses of the NSABP B-13 and the NCCTG N9831 trials suggested that some patients with tumors that were defined as HER2-positive by local pathology and HER2-negative by central pathology derived benefit from trastuzumab, 13,15 raising questions about the impact of heterogeneity and analytical aspects of HER2 testing. The success of clinical trials testing treatment with the HER2-directed antibody–drug conjugate T-DXd in breast cancers with a lower expression – IHC+1 and IHC+2 with a negative fluorescence in situ hybridization (FISH) test, 16,17 previously considered "HER2-negative", created a new terminology for these tumors, and they are now referred to as "HER2-low". However, it remains unclear whether HER2 oncogenic signal transduction plays a role in the progression of HER2-low breast cancer, and if the mechanism underlying the anti-tumor effects of trastuzumab-deruxtecan in HER2-low cancers involves disruption of HER2 signaling or merely better cytotoxic drug delivery. 18 In this review we will focus on 4 main topics: the molecular biology of HER2 in breast cancer and its relevance to HER2-low cancers, the clinical and prognostic significance of HER2-low status in local and metastatic breast cancers treated with standard regimens, the current and future landscape of HER2 targeted therapies for these tumors and the challenges of pathologic assessment of HER2-low BC. To date, several molecular mechanisms of HER2 overexpression in breast cancer have been described, of these, amplification of the HER2 gene (also called erb B-2 and neu ) is the most common mechanism. 19 Breast cancers can have up to 25–50 copies of the HER2 gene and up to 40–100-fold increases in HER2 protein expression, resulting in up to 2 million receptors expressed at the tumor cell surface. 20 Furthermore -Abstract Truncated-